Although the current recommendation for managing hemodynamically unstable pulmonary embolism (PE) is the regimen of 100 mg recombinant tissue plasminogen activator (rtPA) administered over two hours, an accelerated regimen of rtPA (0.6 mg/kg over 15 minutes, maximum 50 mg) has also been described for the management of PE and circulatory arrest. This evidence concerns the gene PLAT and cardiac arrest.